Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation (I&I) indications, oncology, and genetic diseases. The company has developed QuEEN, a discovery engine, to enable its unique target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. ($GLUE) announced an update on their ongoing clinical study. Monte Rosa Therapeutics, Inc. is running a Phase 2 study...

Monte Rosa’s MODeFIRe-1 Trial Pushes GLUE Into a Key Mid-Stage Prostate Cancer Test

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BrightSpring Health Services, Inc. (BTSG), Monte Ros...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, from Wedbush reiterated a Buy rating on Monte Rosa Therapeutics, with a price target of $37.00. The word on The Street ...

Monte Rosa Therapeutics (GLUE) Receives a Buy from Wedbush

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opko Health (OPK), Atea Pharmaceuticals (AVIR) and M...

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Neurocrine (NBIX)...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GLUE	$15.88	+1.08%	1.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GLUE	$15.88	+1.1%	1.03M
3
4
5
6

GLUE

GLUE

Get Monte Rosa Therapeutics, Inc. Data in Excel

Get Monte Rosa Therapeutics, Inc. Data in Excel